Also known as: Anti-Obesity Drug 9604 · hGH Fragment 177-191 · Tyr-hGH Frag 177-191
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue. Unlike full HGH, it stimulates lipolysis and inhibits lipogenesis without affecting growth, IGF-1 levels, insulin sensitivity, or blood glucose — making it a targeted fat-loss agent. FDA GRAS status granted in 2014.
AOD-9604 was developed at Monash University, Australia, by researchers who identified that the lipolytic properties of growth hormone resided in its C-terminal region (residues 177–191). This selective profile is its key differentiator from HGH: it does not elevate IGF-1, it does not affect insulin signaling, and the FDA has granted it GRAS (Generally Recognized as Safe) status as a food ingredient in 2014.
AOD-9604 stimulates lipolysis in adipocytes through a beta-3 adrenergic receptor-like mechanism — independent of the IGF-1 pathway used by full HGH. It activates hormone-sensitive lipase, triggering triglyceride hydrolysis.
Inhibits fatty acid synthase (FAS) expression in adipose tissue, reducing de novo lipogenesis. This dual action creates a net negative fat balance.
Independently stimulates proteoglycan synthesis in cartilage and has been investigated for osteoarthritis treatment via intra-articular injection.
AOD-9604 is the C-terminal fragment (residues 176–191) of human growth hormone, with tyrosine replacing phenylalanine at the N-terminal. It retains HGH's lipolytic properties without stimulating IGF-1 production or causing glucose intolerance — a key safety advantage over full HGH. Phase 2b human trials demonstrated weight loss, but Phase 3 failed to show sufficient effect for drug approval.
Longer cycles are common given the modest effect size and lack of receptor desensitisation concerns. AOD-9604 does not appear to downregulate beta-3 adrenergic receptors with chronic use. Best results reported when combined with caloric deficit and exercise. As a nutraceutical ingredient it has been used continuously at lower oral doses.
Phase 2b/3 clinical trials in Australia showed dose-dependent fat mass reduction without changes in lean mass, IGF-1, or glucose metabolism. FDA GRAS status granted 2014. Cartilage repair Phase 2 showed significant WOMAC improvements in knee OA patients.
Ask anything about AOD-9604 — mechanisms, dosing protocols, interactions, or research comparisons.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…
MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of the mitochondrial ge…